GRAL · GRAIL, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-23 |
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the |
| 2026-09-03 |
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares |
| 2026-08-31 |
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, |
| 2026-08-07 |
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's ( FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory |
| 2026-08-05 |
GRAIL Reports Second Quarter 2026 Financial Results
Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year NHS -Galleri and PATHFINDER 2 Study Results Presented at 2026 |
| 2026-07-30 |
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
MENLO PARK, Calif., July 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, Aug. |
| 2026-07-29 |
GRAIL to Announce Second Quarter 2026 Financial Results
MENLO PARK, Calif., July 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2026 following the close of market on Wednesday, Aug. 5, 2026. |
| 2026-07-16 |
Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
MENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest |
| 2026-06-25 |
GRAIL Completes $110 Million Equity Financing With Samsung Entities
MENLO PARK, Calif., June 25, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. |
| 2026-05-31 |
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers Detected by the Galleri Test Were in Stages I-III MENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- |
| 2026-05-30 |
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri ® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-14 | Morgan Stanley 24th Annual Global Healthcare Conference | Conference |
| 2026-08-11 | Canaccord Genuity 46th Annual Growth Conference | Conference |
| 2026-08-05 | Q2 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-06-09 | Goldman Sachs 47th Annual Global Healthcare Conference | Conference |
| 2026-06-03 | 2026 Jefferies Global Healthcare Conference | Conference |
| 2026-05-31 | GRAIL 2026 ASCO Analyst Call | Event |
| 2026-05-12 | Bank of America Health Care Conference 2026 | Conference |
| 2026-05-05 | Q1 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-03-03 | TD Cowen 46th Annual Health Care Conference | Conference |
| 2026-02-19 | Earnings conference call (announced in 8-K) | Earnings call |
Source: https://investors.grail.com/